*Corresponding author:Chung Owyang MD, Division of Gastroenterology, Department of Internal Medicine, University of Michigan, 3912 Taubman Center, Ann Arbor, MI 48109-5362, Michigan, USA, Tel: +1(734)936-4785; Email: firstname.lastname@example.org
Received: September 03, 2018; Published: September 06, 2018
To view the Full Article Peer-reviewed Article PDF
Small intestinal bacterial overgrowth (SIBO) is often secondary to intestinal dysmotility and several other predisposing conditions. Treatment of SIBO typically includes antibiotics and treatment of underlying etiology. Identification and treatment of the underlying modifiable causes is critical for management of refractory and recurrent SIBO. We report here a case of scleroderma with small bowel dysmotility and bacterial overgrowth, on different occasions the patient failed to respond to Rifaximin. We showed that restoring small bowel motility is critical in maintaining the effectiveness of Rifaximin in the treatment of SIBO. Rifaximin resistance may also develop following prolonged use of antibiotics. Rotation of antibiotic regimen is important to prevent drug resistance.
Keywords: Breath Test; Case Report; Gut Microbiota; Irritable Bowel Syndrome; Nonabsorbable Antibiotics; Octreotide; Prokinetic Agents; Small Intestinal Bacterial Overgrowth
Abbreviations: CI: confidence Interval; FODMAPs: Fermentable Oligo, Di, And Monosaccharides and Polyols; HBT: Hydrogen Breath Test; HE: Hepatic Encephalopathy; IBS: Irritable Bowel Syndrome; SIBO: Small Intestinal Bacterial Overgrowth
We know the financial complexity of Individual read more...
The annual scholar awards from Lupine Publishers honor a selected number read more...